Abstract
INTRODUCTION
BK virus (BKV) is a polyomavirus that causes wides pread subclinical infection at a young age and sub sequently establishes longterm latency in cells of the renal and urinary systems. In recipients of renal allograft transplants and allogeneic hematopoietic stem cell transplants, highlevel BKV replication may lead to overt clinical disease. BKpolyoma virus associated nephropathy (PyVAN) is a major complication of kidney transplantation, occurring in 1%10% of renal transplant recipients [1, 2] . PyVAN is directly associated with graft failure [3, 4] due to progressive interstitial nephritis and indirectly linked to allograft rejection due to immunosuppression reduction (IR), which is the cornerstone of PyVAN treatment [5] . Guidelines currently recommend prospective screening for BKV reactivation posttransplantation, by using urine cytology to detect decoy cells or testing for highlevel BK viruria and/or viremia. In the event of a sustained BK viremia of ≥ 4log copies/mL for more than 3 wk, a renal biopsy is recommended to confirm the diagnosis of PyVAN by demonstrating polyomavirus cytopathic changes with confirmation by immunohistochemical staining [6] . In addition, a prompt reduction of immunosuppression is critical in an attempt to abrogate the fullfledged manifestations of the disease. Although agents with antiBK activity such as leflunomide [7] , cidofovir [8] and quinolones [9] have been used [10] , randomized controlled trials proving their efficacy are lacking.
The positive predictive value of BK viremia at a cut off of 7 × 10 3 copies/mL (approximately 4 log copies/ mL) has been estimated at 50% to 60% for detecting proven PyVAN within 2 to 6 wk but rises to 90% when a threshold of 6log copies/mL is implemented [1, 11, 12] . A lower threshold of 3log copies/mL may increase the sensitivity, leading to the identification of more cases, and earlier in the natural course when intervention may be more effective and graft loss more likely to be averted. In this paper, we aim to assess the incidence of PyVAN and graft loss in a single transplant center while implementing a reduction of immunosuppression at BKV loads of ≥ 3log BKV copies/mL.
MATERIALS AND METHODS
We performed a retrospective analysis of consecutive denovo kidney transplants at YaleNew Haven Hospital (YNHH), who underwent screening for PyVAN screening and prevention, from January 2009 to December 2012. The Yale University Institutional Review Board app roved this study and all procedures conducted were in accordance with the Helsinki Declaration of 1975. Individuals included in the study were above the age of 18 years and underwent primary kidneyonly transplant. Medical records were reviewed for data on demographics, comorbidities, and transplant parameters including type of transplant (deceased or living donor), CMV donor and recipient serostatus, induction and maintenance immunosuppression, presence of delayed graft function (DGF), biopsyproven acute rejection (AR), graft loss and its etiology, last followup visit, deaths, BK viral load (copies/mL) and biopsyproven PyVAN. Graft loss was censored for episodes of death with a functioning graft.
Presumptive PyVAN (PP) was defined as sustained BK viremia ≥ 4-log copies/mL while definitive PyVAN (DP) required cytopathic changes on renal biopsy that were confirmed by positive BKV immunohistochemistry [6] . Renal allograft rejection was graded in accordance with the BANFF working classification of renal allograft pathology [13] . DGF was defined as acute renal failure requiring dialysis within 7 d of transplantation. Graft failure was defined as chronic allograft nephropathy leading to the resumption of chronic renal replacement therapy. Primary outcomes included both presumptive and definitive PyVAN while the secondary outcomes were graft survival and acute rejection.
The YNHH kidney transplant program has been active since 1967 and performs approximately 100 kidney transplantations annually. The standard maintenance immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil and low dose prednisone (510 mg daily). The target tacrolimus trough level for the first 30 d posttransplant was 810 ng/mL and 57 ng/mL thereafter. As part of the institutional protocol for PyVAN screening and prevention, transplant recipient plasma is screened for BKV DNA via quantitative PCR. For the first two years of the study, an NIHdeveloped, realtime BKV PCR assay targeting the viral T antigen gene was used [14] . Due to concerns about potential underquantitation of some BKV subtypes, a multiplex realtime PCR assay developed at the University of Washington (UW) that targets both VP1 and T genes using two primer sets and three probes was implemented in December 2010 [15] . Per protocol, a serum BKV DNA viral load (VL) is obtained at months 1, 3, 6, 9 and 12 posttransplant and in case of worsening graft function. A BKV DNA VL between 3 and 3.99 log copies/mL prompted a 50% dose reduction of mycophenolate mofetil, a reduced target tacrolimus trough level of 5 ng/mL and monthly plasma BKVL until negative. Additionally, mycophenolate mofetil was discontinued and a renal biopsy was with immunohistochemical staining was performed if the serum BKV VL was above ≥ 4log copies/mL PP and DP were treated by reduction of immunosuppression, without adjunctive antiviral treatment.
Statistical analysis
Statistical analysis was performed using SPSS software, version 16.0.0.0. In univariate analyses, χ 2 and Fisher's exact test (when appropriate) were used to evaluate cate gorical variables and MannWhitney U test was used for continuous variables. Predictors of PyVAN were identified using a multivariate logistic regression model. Only variables with a Pvalue < 0.10 on univariate analysis were entered into a stepwise multivariate logistic regression model to identify factors independently associated with Presumptive PyVAN. All tests were doubletailed, with an assumed type 1 error risk a equal to 5%. KaplanMeier survival curves were plotted using GraphPad Prism version 6.03 (GraphPad Software, San Diego, CA, United States).
RESULTS
A total of 330 primary kidney transplant recipients were identified and were followed for a median time of 42 ± 14.7 mo. BK screening data on 11 patients was unavailable and thus they were excluded, leaving 319 patients available for analysis. The median age was 53 years (range 1983), 65.8% were male, 58.9% were white, and 27.0% had diabetes mellitus. A CMV D+/R serostatus was present in 18.2% of transplants and 54.5% of recipients underwent a deceaseddonor kidney transplantation (DDKT). Induction immunosuppressive therapy consisted of basiliximab (44.8%), antithymocyte globulin (37.0%) or daclizumab (17.6%). Maintenance immunosuppressive therapy included both a calcineurin inhibitor and mycophenolate mofetil in 95% of cases and 95% received steroids. Biopsyproven rejection was found in 18.5% (n = 59) of transplant recipients within 0168 wk. Graft loss occurred in 5.3% (n = 17) and PyVANassociated graft los occurred in 0.6% (n = 2). Causes of graft loss included: AR (n = 7), antibody mediated chronic rejection (n = 2), PyVAN (n = 2), CMV nephropathy (n = 1), hypoplastic kidney disease (n = 1), ureteral obstruction (n = 1), renal graft vein thrombosis (n = 1) and unknown cause (n = 2). Death ensued in 6.6% (n = 21) of the sample. A detailed list of demographics is found in Table 1. BK viremia of ≥ 3log copies/mL was detected in 63 (19.7%) recipients. Of these, 47 (14.7%) were subsequently diagnosed with PP at a median time of 25 wk from initial screening. A renal biopsy was performed in 34 of these recipients and 18 (5.6% of the original sample) were confirmed to have DP. Two patients with DP progressed to graft failure and 4 developed AR within 90 d after reduction of immunosuppression.
The majority of the 319 patients included in the study (85.3%) never developed PyVAN. Time to first BK viremia was 190 d in patients with PyVAN and 235 d in those without. Graft loss occurred in 8.5% of patients with PyVAN vs. 4.8% of those without. Graft survival for 1year, 3year and 5years were 99%, 95% and 92% respectively. A KaplanMeier curve of graft survival over time for recipients with and without PP (Figure 1) showed that survival was not significantly different between groups (logrank P = 0.93).
In a univariate analysis of recipients diagnosed with PP (n = 47) compared to recipients without PyVAN (n = 272), black race, DDKT and AR were significantly associated with PyVAN (P < 0.10). In a subsequent multivariate analysis, only DDKT (OR = 2.24; 95%CI to the incidence when using the UW assay (January 2011 to December 2012). In a univariate chisquare analysis of all recipients with first BK viremia, 17/33 (52%) had PyVAN before the assay change versus 30/59 (51%) after the change (P = 0.95).
In addition, we reviewed BKVL data of patients with PP to evaluate for adherence or deviation from the set protocol for posttransplant viral load screening. Among 47 patients with PP, 16 patients underwent screening beyond the recommended interval during the study period and were found to have highlevel viremia on belated screening. For 3 patients, screening was done within 10 d of recommended time point. A summary of patients in whom protocol deviation occurred is found in Table 3 .
DISCUSSION
Though established guidelines recommend a reduction of immunosuppression at a sustained BK viremia of ≥ 4log copies/mL, studies vary significantly with regards to the implemented threshold. Cutoffs of any viremia [16, 17] , of ≥ 3log copies/mL [18] and of ≥ 4log copies/mL [19] have been used with varying rates of PyVAN, graft loss and acute rejection. The incidence of PP in this study, using a lower threshold (≥ 3log copies/mL) of BK viremia for reduction of immunosuppression, was consistent with previously reported rates. In contrast to several investigations conducted in the last decade, which reported rates of graft loss of 15%60% within 5 years of transplant, our incidence of graft loss, was 5.3% [5, 2023] . The incidence of PyVANassociated graft loss in this study (0.6%) was commensurate with more recently published data from 20092013, in which BK associated graft loss ranged from 0%0.85% [1, 19, 2426] . Early reduction of immunosuppression in the setting of BK viremia, though potentially associated with decreased rates of graft loss due to BK nephropathy, carries the potential for increased rates of acute re jection. However, in this study, the incidence of acute rejection (18.5%) was also in keeping with previously reported rates [19, 25] , suggesting that early reduction of = 1.14.54) and AR (OR = 2.42; 95%CI = 1.194.29) were significantly associated with PyVAN (P < 0.05). In this model, PyVAN was not associated with delayed graft function, graft loss or increased mortality. A full description covariates included in the fit-model is found in Table 2 .
While the majority of patients with highlevel viremia were found to have an initial BKVL above 4 log copies/mL, an initial BK viral load between 3 and 4log copies/mL was reported in 27 transplant recipients, all of whom underwent reduction of immunosuppression, without administration of adjunctive antiviral therapy. Of these, 16 (59%) never developed PyVAN while 11 (41%) developed PyVAN within a range of 1139 wk. Among the 11 recipients with PyVAN, 4 were proven by renal biopsy and 7 were presumptive. Two of 27 recipients developed AR and none developed graft loss.
Since the BK PCR assay changed midway through the study, we compared the incidence of PyVAN when using the NIH assay (January 2009 to December 2010) immunosuppression may not necessarily increase the risk of acute rejection. In the past decade, there has been a steady trend towards decreased rates of graft loss. This is thought to be the result of improved diagnostic tools including immunostaining and PCR, which better differentiate virusinduced nephropathy from acute rejection, as well as targeted interventions to promptly identify BK viremia and reduce immunosuppression earlier [27] . A multitude of factors including the potency of induction and maintenance immunosuppressive regimens, demographic differences such as in age and race, frequency of BK viral load monitoring and use of adjunctive antivirals may account for observed differences. The heterogeneity of these studies is further compounded by variation in the sensitivity, lower limit of detection of the BK virus PCR assay and most importantly a lack of equivalence of quantitation between different assays. Complicating matters is the presence of multiple viral subtypes, some of which (serotypes 3 and 4) are particularly prone to underquantitation. In this study, we found no statistical difference in the number of patients with any viremia when sequentially comparing two different molecular assays but results from laboratories using different assays have been shown to vary significantly, even when performed on the same sample [15] . Since specific BK VL cutoffs are used to trigger interventions, assay variability is a critical issue and may indeed explain the variability in thresholds used across different transplant centers. A BK PCR standard that can be applied across laboratories is paramount in implementing a uniform BK viremia threshold for reduction of immunosuppression. In 2015, the World Health Organization (WHO) took steps to establish an international standard for BKV DNA nucleic acid amplification technique-based assays, using purified virions from BKV infected cell cultures [28] . This standard, however, has not yet been widely adopted and additional in-vitro verification data and invivo clinical data are needed to ascertain its performance characteristics. Until then, performing serial testing on individual patients using the same assay within the same laboratory, eschewing overinterpretation of small viral load changes as biologically important and establishing center-specific viral load cutoffs to guide clinical decision making in local Azar MM et al . Early reduction of immunosuppression for BK patient populations will facilitate the interpretation of current BK viral load testing. Certainly, adequate implementation of screening protocols is another critical factor in optimizing preven tative strategies. In our study, a substantial number of patients with presumptive PyVAN did not adhere to the scheduled BKVL screening timepoints. Strict adherence to screening protocol is likely to reduce the incidence of PyVAN by identifying viremia earlier and allowing for early interventions.
Instituting an early reduction of immunosuppression at ≥ 3log copies/mL, in the absence of adjunctive antivirals, was effective at preventing PyVAN in our center and may be associated with a lower incidence of graftloss without an increased rate of acute re jection compared to published data. However, efforts to implement the WHO BK standard will be key in establishing a universal preventive strategy for PyVAN that is both highly effective and widely applicable.
COMMENTS

Background
Polyoma virus associated nephropathy (PyVAN) caused by BK virus (BKV) is a major complication occurring in 1%-10% of renal transplant recipients that is directly associated with graft loss and indirectly associated with graft rejection.
Research frontiers
Guidelines currently recommend prospective screening for BKV reactivation post-transplantation, with reduction of immunosuppression at > 4-log copies/mL of BK virus. Additional research is needed to determine the best screening strategy.
Innovations and breakthroughs
The present study describes results of early reduction of immunosuppression (at ≥ 3-log copies/mL) in the absence of antivirals. This strategy effective at preventing PyVAN and was associated with a lower incidence of graft-loss without a reciprocal increase in the incidence of acute rejection.
Applications
Early reduction of immunosuppression should be considered as a strategy for prospective screening for BKV reactivation post-transplantation.
Terminology
PyVAN is a disease of the kidney that results from reactivation of BK virus in the setting of immune suppression, leading to cytopathic effect on renal tubular cells and secondary inflammation.
